Post-Traumatic Stress Disorder (PTSD) Research

The Mood and Anxiety Disorders Program (MAP) is researching a range of new treatments for post-traumatic stress disorder (PTSD). Our studies include research into finding novel uses for current medications such as ketamine (an FDA-approved anesthetic) and developing new drugs.

Clinical Trials for Post-Traumatic Stress Disorder (PTSD)

MAP is currently seeking individuals interested in participating in the following clinical trials for PTSD.

• An inhibitor of the “stress hormone” (corticotropin releasing factor antagonist) for the Treatment of PTSD: Investigates the efficacy of using a corticotropin releasing factor antagonist to inhibit the release of stress hormones in patients with PTSD.
• Ketamine as a Rapid Treatment for Post-Traumatic Stress Disorder: Investigates the efficacy of ketamine in patients with PTSD.

To participate in one of our clinical trials for Mood and Anxiety Disorders or to learn more about eligibility, please contact Julia Morgan (212-241-7906; julia.morgan@mssm.edu).